

Declaration for California Compliance Law

Veracyte is a global diagnostics company whose tests provide trustworthy and actionable answers that improve care throughout the patient journey. Our tests leverage innovations in genomic technology and machine learning to enable more confident diagnostic, prognostic and treatment decisions in challenging diseases such as lung cancer, prostate and bladder cancers, thyroid cancer, breast cancer, colon cancer and idiopathic pulmonary fibrosis. We are creating new standards of care by enabling more patients to avoid unnecessary procedures, speeding time to diagnosis and treatment, and removing costs from the healthcare system. Compliance is one of the corporate values that shapes Veracyte's business practices. Establishing and maintaining an effective compliance program is a key component of this commitment. As part of our compliance efforts, Veracyte has adopted a comprehensive compliance program designed to advance our corporate values and prevent and detect violations of our business standards, which accords with California Health and Safety Code § 119402 (S.B 1765).

The Veracyte compliance program is in accordance with the Compliance Program Guidance published by the Office of the Inspector General of the U.S. Department of Health and Human Services. Veracyte's primary business is diagnostic testing services from its CLIA certified laboratories with a subset of the business dedicated to the design, manufacture and sale of diagnostic tests, some of which are regulated as a medical device. As such, the Veracyte compliance program reflects our adoption of policies and procedures appropriate to our company, including compliance with the AdvaMed Code of Ethics on Interactions with Healthcare Professionals. Substantially similar to the PhRMA Code referenced in California Health and Safety Code § 119402, the AdvaMed Code addresses potential risk areas that apply to the unique environment of the medical device industry. Therefore, consistent with the OIG Guidance, the Veracyte compliance program includes policies for compliance with the AdvaMed Code.

1. Leadership and Structure

The Chief Compliance Officer has ultimate responsibility for developing, overseeing, and monitoring the operation of Veracyte's compliance program. In this role, the Compliance Officer has the authority to exercise appropriate professional judgment regarding the compliance program, and to develop and implement revisions and improvements as needed to maintain an effective compliance program. The Compliance Officer is part of the Executive Team, has independent reporting authority and responsibility to our Regulatory and Compliance Committee of the Board of Directors for compliance-related matters.

2. Written standards

Veracyte's Code of Conduct ("Code") is our statement of ethical and compliance principles that guide our daily operations. The Code establishes expectations that management, employees, contractors, and agents of the business are expected to follow, as well as standards to help ensure compliance with applicable laws and company policies. To emphasize the importance of the principles and guidelines contained in the Code, we require each of our employees to certify that he/she/they has read and agrees to abide by all of Veracyte's policies and procedures.

In addition to the Code, Veracyte written policies and procedures emphasize individual and corporate responsibility for compliance with all applicable laws and regulations and adherence to the highest ethical standards. Veracyte's written policies govern activities involving communicating with customers

about the appropriate use of our products including appropriate instruction, education, training, service and technical support required for the safe and effective use of our products.

Annual Spending Limit

For purposes of complying with the California Health and Safety Code 119402, Veracyte has established a maximum annual aggregate dollar limit of \$2,000 for gifts, promotional materials or activities provided to California health care professionals. This dollar limit represents a spending cap, not a goal or average, and typically the amount spent per physician is anticipated to be substantially less than this maximum amount. Waiver of the limit would require the approval of the Chief Compliance Officer. However, as Veracyte is enrolled in Federal healthcare programs and is subject to Stark law, non-monetary compensation provided to a physician that orders Medicare-reimbursable tests from Veracyte must not exceed the threshold for that calendar year (i.e., \$429 for 2021).

To attempt to assure that health care professionals ("HCP") fully understand our products and services, Veracyte representatives may take time to explain the benefits and risks associated with them, as well as the relevant clinical efficacy studies, where appropriate. Some of these informational and educational presentations may take place over the course of a modest meal to avoid taking HCPs away from important time with their patients.

On occasion, Veracyte may provide medically relevant and patient-oriented items to HCPs that conform to the AdvaMed Code. Some examples include anatomical models, patient education charts and information that is useful for patients in understanding or managing their condition and/or treatment.

3. Education and Training of Veracyte Staff

Education and training are essential to effectively communicating our standards and requirements to our personnel and enabling them to perform in accordance. As part of our commitment to ethics and compliance, Veracyte conducts annual health care compliance training of relevant team members regarding their legal and ethical obligations and includes an annual team member certification. Our training encompasses applicable guidelines governing our compliance program and advises team members of the consequences of failure to comply with our compliance program. Veracyte regularly reviews and updates its training programs and deploys additional training on an ad hoc basis.

4. Internal Lines of Communication

Veracyte is committed to fostering an active and healthy dialogue between management and employees regarding ethical and compliance-related matters. Veracyte understands and believes that its personnel must not just know how to access compliance-related resources, they must feel comfortable doing so without fear of retaliation. We have adopted policies and procedures that strongly encourage all personnel to report potential suspected compliance violations, including measures intended to ensure that good faith reports will not subject the person making the report to retaliation. Veracyte has engaged EthicsPoint as a tool to allow personnel to report potential compliance violations 24 hours a day, 365 days a year. EthicsPoint toll-free helpline can be reached at (877) 813-7431, or online at <https://veracyte.ethicspoint.eu/>. Information about EthicsPoint is given to all personnel as part of new hire orientation, continuing compliance training, and is made available via our website.

5. Auditing and Monitoring

Veracyte's compliance program includes compliance-related monitoring and auditing functions to help evaluate on-going compliance with our compliance-related policies and procedures. Consistent with the OIG Guidance, we take a number of factors into consideration when determining the nature, extent, and frequency of our compliance monitoring and auditing activities. New legal requirements, developments in business practices, and similar considerations may result in new or revised compliance-related monitoring or auditing programs. We review our monitoring and auditing activities on a regular basis to help ensure that significant compliance-related risks are appropriately addressed.

6. Responding to Potential Violations

Each employee is responsible and accountable for adhering to all applicable laws and regulations as well as Veracyte policies and procedures. Veracyte employees who fail to meet these responsibilities are subject to appropriate disciplinary action by Veracyte, which may include termination.

7. Corrective Action Procedures

Veracyte works on an on-going basis to help ensure compliance with state and federal health care laws, as well as with our internal compliance-related policies and procedures. We believe that our compliance program increases the likelihood of preventing or identifying unlawful and unethical behavior. We recognize, however, that even an effective compliance program will not prevent all violations. Our compliance program, therefore, requires Veracyte to respond promptly to potential violations of law or Veracyte policy, take appropriate disciplinary action, assess whether the violation may be due to gaps in our policies, procedures, practices, or internal controls, and take appropriate corrective action to prevent or limit future violations.

Declaration

As of the date of this declaration to the best of our knowledge, Veracyte is in compliance with this compliance program and the provisions of the California Health and Safety Code § 119402 in all material respects. Consistent with Veracyte's understanding of the California statute, this declaration is limited to those activities undertaken by Veracyte that are directed to California. Veracyte makes this declaration, in good faith, in the absence of clarifying regulations or guidance from the State of California. This declaration reflects our consideration of the OIG Guidance, which gives broad discretion to manufacturers in the development, design, and definition of the scope of compliance programs.

Copies of this declaration and the Compliance Program may be obtained by calling corporate headquarters at (844) 464-5864.

Dated: November 17, 2021